Alnylam Pharmaceuticals, Inc.
Methods and compositions for treating a proprotein convertase subtilisin kexin (PCSK9) gene-associated disorder

Abstract:

The invention relates to methods of inhibiting the expression of a PCSK9 gene in a subject, as well as therapeutic and prophylactic methods for treating subjects having a lipid disorder, such as a hyperlipidemia using RNAi agents, e.g., double-stranded RNAi agents, targeting the PCSK9 gene.